Ovarian cancer: ten-year experience in a community hospital. 1987

G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
Division of Radiotherapy, Centro di Riferimento Oncologico, Aviano Pordenone, Italy.

We reviewed 187 patients with epithelial ovarian cancer treated, from 1975 to 1985, at the Division of Radiotherapy and Medical Oncology, Pordenone General Hospital, Italy. It seemed of interest to report an experience carried out in a community hospital in a consecutive unselected series of patients affected by ovarian cancer. Survival time was evaluated from the day of the primary surgical approach to the end of the study (March 1985). The aim of the study was to confirm in our patient population the importance of some already recognised prognostic factors that influence survival (age, stage, histology, grade, type of surgery and residuum). We also analyzed the effect of the treatment variables chemotherapy and radiotherapy on survival. The general pattern of prognostic factors appears to be in agreement with reports in the literature. In our experience, residual disease and stage were the main important prognostic factors; grade and histology had a secondary relevance, and age did not seem to be a prognostic factor in our population. New chemotherapy regimens and/or radiotherapy did not appear to improve survival. In fact, comparison of the results obtained from 1975-1979 and from 1980-1985 (when more aggressive surgery and cisplatin-containing regimens were employed) showed no statistically significant difference in survival rate. Our data suggest that patients at an early stage can receive a satisfactory quality of care in a general hospital with oncology facilities, provided the surgeon and the pathologist are experienced in ovarian cancer. Patients at stage III but completely surgically resected can also be adequately treated. Patients with advanced disease, considering the lack of established efficacious treatments, should be referred to specialized centers, where new drugs or experimental strategies can be tested.

UI MeSH Term Description Entries
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006764 Hospitals, Community Institutions with permanent facilities and organized medical staff which provide the full range of hospital services primarily to a neighborhood area. Community Hospital,Community Hospitals,Hospital, Community
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
December 1981, British journal of obstetrics and gynaecology,
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
December 1980, Southern medical journal,
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
December 1979, The Journal of the Medical Society of New Jersey,
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
March 1978, Hawaii medical journal,
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
February 1983, Journal of the South Carolina Medical Association (1975),
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
June 1982, Journal of surgical oncology,
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
July 1985, Connecticut medicine,
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
March 2007, Diagnostic cytopathology,
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
October 1988, The Journal of the Florida Medical Association,
G Franchin, and D Crivellari, and S Tumolo, and C Scarabelli, and A De Paoli, and S Frustaci, and A Ciampi, and L Del Ben, and R Talamini, and M Trovò
January 1988, American journal of diseases of children (1960),
Copied contents to your clipboard!